Your browser version may not work well with NCBI's Web applications. More information here...
1: Cancer Treat Rep. 1982 Sep;66(9):1759-61.Links

Phase I study of 13-cis-retinoic acid toxicity.

Band PR, Besner JG, Leclaire R, Girard C, Diorio G, Deschamps M, Gélinas M, Larochelle D.

A phase I study of 13-cis-retinoic acid was done in 16 patients with head and neck malignancies using a modified Fibonacci search scheme, with individual doses ranging from 20 to 120 mg/m2. Drug doses greater than 60 mg/m2 induced intense headaches, urethritis, desquamative dermatitis, vertigo, and ataxia. The severity of these side effects precludes the use of 13-cis-retinoic acid as a potential chemopreventive agent at doses greater than 60 mg/m2.

PMID: 7116351 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Tretinoin (Vesanoid® )

    Tretinoin is used to treat acute promyelocytic leukemia (APL; a type of cancer in which there are too many immature blood cells in the blood and bone marrow) in people who have not been helped by other types of chemother...

  • Source: AHFS Consumer Medication Information